Solid Biosciences (NASDAQ:SLDB) Stock Price Up 5.5% on Analyst Upgrade

Shares of Solid Biosciences Inc. (NASDAQ:SLDB) shot up 5.5% on Thursday after Truist Financial upgraded the stock to a strong-buy rating. The stock traded as high as $7.61 and last traded at $7.63. 335,353 shares were traded during mid-day trading, a decline of 75% from the average session volume of 1,345,952 shares. The stock had previously closed at $7.23.

SLDB has been the subject of several other research reports. Chardan Capital reiterated a “buy” rating and issued a $15.00 price target on shares of Solid Biosciences in a research report on Friday, March 20th. Citigroup reissued a “market outperform” rating on shares of Solid Biosciences in a research report on Wednesday, December 17th. Guggenheim assumed coverage on shares of Solid Biosciences in a research note on Friday, March 20th. They issued a “buy” rating and a $26.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Solid Biosciences in a report on Monday. Finally, JPMorgan Chase & Co. increased their target price on shares of Solid Biosciences from $11.00 to $12.00 and gave the stock an “overweight” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $16.09.

Insider Buying and Selling at Solid Biosciences

In other Solid Biosciences news, insider Gabriel Brooks sold 12,616 shares of the business’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $6.44, for a total value of $81,247.04. Following the transaction, the insider directly owned 84,092 shares of the company’s stock, valued at approximately $541,552.48. The trade was a 13.05% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Kevin Tan sold 5,404 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $5.82, for a total transaction of $31,451.28. Following the transaction, the chief financial officer owned 99,422 shares of the company’s stock, valued at approximately $578,636.04. The trade was a 5.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 597,672 shares of company stock valued at $3,816,546. Corporate insiders own 1.90% of the company’s stock.

Trending Headlines about Solid Biosciences

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Truist upgraded SLDB to “Strong‑Buy”, adding a near‑term positive catalyst that supports momentum and investor confidence. Zacks Article
• Positive Sentiment: JPMorgan raised its price target from $11 to $12 and maintained an “Overweight” rating — a ~55% upside vs. the current share level — which can attract institutional interest and buying. Benzinga Article
• Positive Sentiment: HC Wainwright raised multiple near‑term EPS estimates (Q1–Q4 2026) and materially improved its FY2026 outlook (from ~($2.12) to ($1.43)), while keeping a “Buy” rating and a $20 price target — signaling better expected near‑term performance and strong long‑term upside (FY2029–2030 turn to profitability). HC Wainwright Coverage
• Neutral Sentiment: Analyst optimism is concentrated in price targets and model revisions rather than new clinical readouts or revenue — the moves reflect expectations, not confirmed commercial progress; watch for upcoming company data or milestones to sustain gains. MarketBeat Summary
• Negative Sentiment: Consensus remains that Solid is not yet profitable (street FY current consensus still negative), so the stock is vulnerable to execution risk, trial setbacks, or any misses vs. these raised expectations. MarketBeat Financials

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SLDB. MetLife Investment Management LLC raised its position in Solid Biosciences by 10.4% in the fourth quarter. MetLife Investment Management LLC now owns 33,202 shares of the company’s stock worth $187,000 after acquiring an additional 3,124 shares in the last quarter. Quantum Private Wealth LLC boosted its position in shares of Solid Biosciences by 3.9% during the 3rd quarter. Quantum Private Wealth LLC now owns 94,231 shares of the company’s stock worth $581,000 after purchasing an additional 3,500 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Solid Biosciences by 208.6% during the 2nd quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock worth $29,000 after purchasing an additional 4,063 shares during the period. Ameritas Investment Partners Inc. increased its holdings in shares of Solid Biosciences by 205.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock valued at $33,000 after purchasing an additional 4,534 shares in the last quarter. Finally, Intech Investment Management LLC lifted its stake in shares of Solid Biosciences by 15.2% in the fourth quarter. Intech Investment Management LLC now owns 34,485 shares of the company’s stock valued at $194,000 after purchasing an additional 4,539 shares during the period. 81.46% of the stock is owned by hedge funds and other institutional investors.

Solid Biosciences Stock Up 6.9%

The business’s fifty day moving average is $6.57 and its 200 day moving average is $5.84. The stock has a market cap of $602.24 million, a PE ratio of -3.83 and a beta of 2.65.

Solid Biosciences (NASDAQ:SLDB) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.01. As a group, analysts predict that Solid Biosciences Inc. will post -2.84 EPS for the current year.

About Solid Biosciences

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.